Suzhou Abogen Biosciences Co., Ltd.
๐จ๐ณChina
- Country
- ๐จ๐ณChina
- Ownership
- Holding
- Established
- 2019-01-10
- Employees
- 501
- Market Cap
- -
- Website
- http://www.abogenbio.com
Phase โ /โ ก Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT06088004
- Locations
- ๐จ๐ณ
Guangxi Medical University Cancer Hospital, Nanning, China
๐จ๐ณCancer Hospital Chinese Academy of Medical Sciences, Beijing, China
๐จ๐ณSun Yat-sen University Cancer Center, Guangzhou, China
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 14168
- Registration Number
- NCT05636319
- Locations
- ๐ต๐ญ
Premiere Medical Center, Cabanatuan, Philippines
๐ต๐ญSilang Medical Center, Cavite, Philippines
๐ฆ๐ชAI Kuwait Hospital, Dubai, United Arab Emirates
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05434585
- Locations
- ๐ฎ๐ฉ
Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
๐ฎ๐ฉPersahabatan Hospital, Jakarta, Indonesia
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05433194
- Locations
- ๐ฆ๐ช
AL Kuwait Hospital, Dubai, United Arab Emirates
ยฉ Copyright 2024. All Rights Reserved by MedPath